Journal of Oncology & Targeted Therapies
Aims and Scope – Journal of Oncology & Targeted Therapies
The aim of the Journal of Oncology & Targeted Therapies: Open Access is to increase awareness, inspire innovation, and promote research interest in the expanding fields of oncology and targeted cancer therapies. The journal serves as a platform to share meaningful advances in cancer biology, diagnostics, treatment strategies, and personalized medicine.
To support this mission, the Journal of Oncology & Targeted Therapies welcomes a wide range of scholarly contributions, including: original research articles, review articles, case reports, image articles, short communications, commentaries, opinions, theses, letters to the editor, editorials, science guidelines.
These submissions provide valuable insights into the mechanisms of cancer development, progression, and targeted therapeutic approaches, enhancing our understanding of oncology as a multidisciplinary field.
The journal encompasses a wide range of topics in cancer research, including but not limited to:
- Targeted therapies and personalized medicine
- Molecular oncology and tumor genomics
- Chemotherapy and drug resistance
- Immunotherapy and cancer vaccines
- Biomarkers for early detection and prognosis
- Signal transduction in cancer cells
- Combination therapies and clinical protocols
- Precision radiotherapy and radiosensitizers
- Cancer pharmacology and drug delivery
- Cancer stem cells and tumor microenvironment
- Translational and clinical oncology
- Onco-nanomedicine and bioengineering
- Genetic and epigenetic changes in cancer
- Artificial intelligence in cancer diagnostics
- Innovations in oncology devices and robotics
- Pediatric, geriatric, and rare cancers
- Ethical and regulatory aspects in oncology research
Journal of Oncology & Targeted Therapies: Open Access strongly supports the Open Access initiative. All articles—whether abstracts or full texts—are published in HTML, PDF, and XML formats and made freely accessible online immediately after publication, ensuring global visibility and unrestricted access to knowledge.
The journal is published by IBMSR Journals and remains committed to keeping pace with the latest advances in oncology and targeted therapy research.